Testing genetic modifiers of behavior and response to atomoxetine in autism spectrum disorder with ADHD.

ABSTRACT:

Background

Frequent non-pathogenic genetic variants may act as moderators of phenotypic severity for complex disorders such as autism spectrum disorder (ASD). We previously identified polymorphisms affecting mRNA expression of candidate genes, including tryptophan hydroxylase 2 (TPH2), dopamine beta hydroxylase (DBH), and dopamine transporter (DAT, SLC6A3).

Method

We compare genotypes and (1) clinical response to atomoxetine, (2) scores from the Autism Diagnostic Interview-Revised (ADI-R), and (3) severity of Attention Deficit Hyperactivity Disorder (ADHD) symptoms in a cohort of patients with ASD from multiple study sites.

Results

There was no association between CYP2D6 metabolizer status and atomoxetine response. TPH2 rs7305115 genotype w

SUBMITTER: Barrie ES 

PROVIDER: S-EPMC6128165 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature